Canton Strategic Holdings (CNTN) EBIAT (2021 - 2026)
Canton Strategic Holdings posted quarterly EBIAT of -$47.3 million for Q1 2026, down 1762.66% year-on-year from $2.8 million in Q1 2025, and down 60.94% on a QoQ basis from -$29.4 million in Q4 2025.
Canton Strategic Holdings (CNTN) has 6 years of EBIAT data on file, last reported at -$47.3 million in Q1 2026.
- For the quarter ending Q1 2026, EBIAT fell 1762.66% year-over-year to -$47.3 million; the trailing twelve-month figure through Mar 2026 stood at -$80.7 million (down 546.61% YoY), and the FY2025 full-year result was -$35.9 million, down 194.45% from the prior year.
- EBIAT for Q1 2026 stood at -$47.3 million, down from -$29.4 million in the prior quarter.
- Across five years, EBIAT topped out at -$1.6 million in Q2 2022 and bottomed at -$47.3 million in Q1 2026.
- The 5-year median for EBIAT is -$2.3 million (2023), against an average of -$6.7 million.
- The widest annual swing landed in 2025, when EBIAT soared 44.63%; it then plunged 1762.66% in 2026.
- A 5-year view of EBIAT shows it stood at -$1.8 million in 2022, then plunged by 40.04% to -$2.5 million in 2023, then slumped by 54.44% to -$3.8 million in 2024, then tumbled by 669.98% to -$29.4 million in 2025, then plunged by 60.94% to -$47.3 million in 2026.
- The last three EBIAT figures came in at -$47.3 million (Q1 2026), -$29.4 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | -47.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.34 Mn |
| Dec 31, 2025 | -29.42 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -1.86 Mn |
| Mar 31, 2025 | -2.54 Mn |
| Dec 31, 2024 | -3.82 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -1.82 Mn |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -2.69 Mn |
| Dec 31, 2022 | -1.77 Mn |
| Sep 30, 2022 | -2.13 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -2.94 Mn |
| Dec 31, 2021 | 2.45 Mn |
| Sep 30, 2021 | -853,436.00 |
| Jun 30, 2021 | -1.56 Mn |
| Mar 31, 2021 | -2.25 Mn |